Showing results (471-480 of 641) with videos related to

Sort By:
Pageof 65
Physical Review Letters|October 5, 2025
Femtosecond-Laser-Delamination Cavities for Resonant Acousto-Magneto-PlasmonicsPavel Varlamov, Akira Barros, Aditya Swaminathan, et al.
The American Journal of Clinical Nutrition|October 16, 2018
No consistent evidence of a disproportionately low resting energy expenditure in long-term successful weight-loss maintainersDanielle M Ostendorf, Edward L Melanson, Ann E Caldwell, et al.
Developmental Cell|April 29, 2022
Functional genetic screen identifies ITPR3/calcium/RELB axis as a driver of colorectal cancer metastatic liver colonizationRyan H Moy, Alexander Nguyen, Jia Min Loo, et al.
European Journal of Immunology|March 1, 2023
Discriminating promiscuous from target-specific autoantibodies in COVID-19Mikhail Lebedin, Clara Vázquez García, Lisa Spatt, et al.
Journal of Personality and Social Psychology|June 21, 2006
Is the genetic structure of human personality universal? A cross-cultural twin study from North America, Europe, and AsiaShinji Yamagata, Atsunobu Suzuki, Juko Ando, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|April 11, 2024
Effectiveness, safety and impact of guselkumab on sexuality and perceived stigmatization in patients with psoriasis in routine clinical practice: Week 28 results from the prospective German multicentre G-EPOSS studyS Gerdes, R Ostendorf, A Süß, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|April 25, 2017
Optimized expression-based microdissection of formalin-fixed lung cancer tissueMarkus Grafen, Thurid R Hofmann, Andreas H Scheel, et al.
Journal of the American Society of Nephrology : JASN|August 12, 2005
Y-box protein 1 mediates PDGF-B effects in mesangioproliferative glomerular diseaseClaudia R C van Roeyen, Frank Eitner, Sandra Martinkus, et al.
Kidney International|October 5, 2007
CCN3 is a novel endogenous PDGF-regulated inhibitor of glomerular cell proliferationC R C van Roeyen, F Eitner, T Scholl, et al.
The British Journal of Dermatology|February 28, 2016
A randomized, double-blind, phase III, multicentre study to evaluate the safety and efficacy of BF-200 ALA (Ameluz(®) ) vs. placebo in the field-directed treatment of mild-to-moderate actinic keratosis with photodynamic therapy (PDT) when using the BF-RhodoLED(®) lampU Reinhold, T Dirschka, R Ostendorf, et al.
Pageof 65